Summary & Overview
HCPCS J1454: Fosnetupitant 235 mg and Palonosetron 0.25 mg Injection
HCPCS Level II code J1454 represents the combined injectable antiemetic formulation of fosnetupitant 235 mg with palonosetron 0.25 mg used to prevent chemotherapy-induced nausea and vomiting. As a drug administration code, it captures a single intravenous therapeutic agent delivered in outpatient infusion settings. Nationally, accurate coding for combination antiemetic products matters for clinical workflow, billing consistency, and payer coverage determinations for oncology supportive care.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code and its clinical context, plus what to expect when reviewing payer coverage and reimbursement benchmarking: how the code maps to outpatient infusion services, common sites of service, and implications for billing workflows. The publication outlines benchmarks and policy updates where available, summarizes payer coverage patterns, and highlights considerations for service line reporting and cost tracking. Data fields not provided in the source are identified as unavailable. This summary is intended for national audiences including billing managers, oncology clinic administrators, and policy analysts seeking a clear reference for HCPCS Level II code J1454.
Billing Code Overview
HCPCS Level II code J1454 describes an injection of fosnetupitant 235 mg and palonosetron 0.25 mg. This combination product is an antiemetic formulation intended to prevent chemotherapy-induced nausea and vomiting.
Service type: Therapeutic drug administration (single-injection, IV)
Typical site of service: Hospital outpatient infusion center or clinic-based infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient scheduled to receive moderately or highly emetogenic chemotherapy (for example, platinum- or anthracycline-based regimens) in an outpatient infusion center. Prior to chemotherapy, the oncology nurse verifies prior authorization and allergy status, reviews the antiemetic regimen ordered by the oncologist, and prepares the fixed-dose intravenous combination of fosnetupitant 235 mg and palonosetron 0.25 mg (J1454). The medication is administered as part of an antiemetic prophylaxis protocol given on Day 1 of chemotherapy to reduce acute and delayed chemotherapy-induced nausea and vomiting. Documentation includes the drug name and HCPCS code J1454, lot number, dose and route, time of administration, infusion site of service (typically outpatient hospital infusion center or physician office), and patient response. Common clinical workflow steps: ordering by the oncologist, pharmacist verification and preparation, nurse administration, monitoring for immediate hypersensitivity or infusion reactions, and documentation of effectiveness and any adverse events for subsequent visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier applies; standard billing for the drug service |